AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18506181 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib at 50 mg (cohort 1), 100 mg (cohort 2a), or 75 mg (cohort 2b) day(‐1) for up to six cycles with docetaxel (75 mg m(‐2)) and carboplatin (AUC 5) on day 1 of a 3-week cycle.
Number of subjects: 45
Study 18506181 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent maintenance erlotinib at 100-150 mg day(‐1) after initial treatment.
Number of subjects: 45
Study 16395617 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior hemivertebrectomy followed by posterior excision, posterior instrumentation, and fusion.
Number of subjects: 26
Study 16395617 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior excision followed by anterior hemivertebra body excision, anterior instrumentation, and fusion.
Number of subjects: 26
Study 16395617 — intervention group
Group type: COMPARATOR
Intervention: Both groups (anterior and posterior techniques)
Number of subjects: 26
Study 14604045 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized and stratified investigation by telephone interview
Number of subjects: 502
Study 10928428 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg progesterone vaginal gel) twice daily
Number of subjects: 345
Study 10928428 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg progesterone vaginal gel) once daily
Number of subjects: 345
Study 10928428 — intervention group
Group type: COMPARATOR
Intervention: i.m. progesterone (100 mg)
Number of subjects: 345
Study 10928428 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (Crinone and i.m. progesterone)
Number of subjects: 345
Study 8793333 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.124 IU/kgBW/week
Number of subjects: 12
Study 8793333 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.250 IU/kgBW/week
Number of subjects: 12
Study 8793333 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375 IU/kgBW/week
Number of subjects: 12
Study 8793333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1345029 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of ioxaglate
Number of subjects: 20
Study 1345029 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of iopamidol
Number of subjects: 20
Study 1345029 — intervention group
Group type: COMPARATOR
Intervention: Control measures (blood pressure, heart rate, circulating granulocytes)
Number of subjects: 20
Study 6205060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g
Number of subjects: 78
Study 6205060 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin 2 g
Number of subjects: 78
Study 29712745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment
Number of subjects: 0
Study 29712745 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure treatment
Number of subjects: 0
Study 28258928 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol 400mg every 12h for 8 weeks
Number of subjects: 92
Study 28258928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 26237001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% 10 mL
Number of subjects: 26
Study 26237001 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.1% 30 mL
Number of subjects: 26
Study 24144761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 60
Study 24144761 — intervention group
Group type: COMPARATOR
Intervention: Oral NSAIDs
Number of subjects: 60
Study 21943294 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help therapy (6-week duration, based on Cognitive Behavioural Therapy, Motivational Interviewing, and self-control practices)
Number of subjects: 0
Study 21943294 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help therapy
Number of subjects: 0
Study 21943294 — intervention group
Group type: COMPARATOR
Intervention: Weekly psycho-educative information with a quiz (control group)
Number of subjects: 0
Study 17522607 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoscalim
Number of subjects: 20
Study 17522607 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycollagene
Number of subjects: 20
Study 17522607 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 20
Study 17522607 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin
Number of subjects: 20
Study 16582527 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I periodontal treatment including scaling, root planning, and 0.2% chlorhexidine mouth rinse for one week
Number of subjects: 30
Study 16582527 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 16582527 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I periodontal treatment
Number of subjects: 30
Study 14513774 — intervention group
Group type: EXPERIMENTAL
Intervention: Toki‐shakuyaku‐san
Number of subjects: 25
Study 14513774 — intervention group
Group type: COMPARATOR
Intervention: Oral iron preparation
Number of subjects: 25
Study 10725488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative lymph node palpation
Number of subjects: 126
Study 10725488 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 126
Study 8736653 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline Turbuhaler (0.5 mg t.i.d.)
Number of subjects: 32
Study 8736653 — intervention group
Group type: COMPARATOR
Intervention: salbutamol Rotahaler (0.4 mg t.i.d.)
Number of subjects: 32
Study 8736653 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline Turbuhaler
Number of subjects: 32
Study 8736653 — intervention group
Group type: COMPARATOR
Intervention: salbutamol Rotahaler
Number of subjects: 32
Study 1434838 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD (for induction and consolidation) followed by monthly myelosuppressive maintenance for 3 years; second induction course either TAD or HAM for patients less than 60 years.
Number of subjects: 900
Study 1434838 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic BMT in first CR
Number of subjects: 900
Study 1434838 — intervention group
Group type: COMPARATOR
Intervention: Autologous BMT in first CR
Number of subjects: 900
Study 3893101 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837
Study 3893101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 3893101 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician diagnosis
Number of subjects: 3837
Study 3893101 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire
Number of subjects: 3837
Study 3893101 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician diagnosis and Questionnaire
Number of subjects: 3837
Study 29423715 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid (ZOL)
Number of subjects: 306
Study 27624507 — intervention group
Group type: EXPERIMENTAL
Intervention: Citywide care coordination program combined with an ED care coordination information system
Number of subjects: 165
Study 24558403 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant Canarypox (CP) vaccine vCP205 via inguinal-subcutaneous injection
Number of subjects: 18
Study 24558403 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant Canarypox (CP) vaccine vCP205 via deltoid-intramuscular injection
Number of subjects: 18
Study 24558403 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant Canarypox (CP) vaccine vCP205
Number of subjects: 18
Study 24558403 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 22683442 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (IT) group, n=11
Number of subjects: 22
Study 22683442 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition (WL) group, n=11
Number of subjects: 22
Study 20530307 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Management in Pediatrics, a 9‐hour behavior change curriculum based on brief MI plus written feedback on communication skills
Number of subjects: 18
Study 20530307 — intervention group
Group type: COMPARATOR
Intervention: Control residents
Number of subjects: 18
Study 18410863 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezius squeezing test
Number of subjects: 45
Study 16765490 — intervention group
Group type: EXPERIMENTAL
Intervention: Priorix
Number of subjects: 295
Study 16765490 — intervention group
Group type: COMPARATOR
Intervention: MMR-II
Number of subjects: 295
Study 12862324 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress exposure (55 degrees C, 30% humidity)
Number of subjects: 6
Study 10950002 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal sphincterotomy
Number of subjects: 90
Study 10950002 — intervention group
Group type: COMPARATOR
Intervention: Topical nitroglycerin 0.25% tid
Number of subjects: 90
Study 8773735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 whole eggs (E)
Number of subjects: 12
Study 8773735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 egg yolks (Y)
Number of subjects: 12
Study 8773735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 egg whites
Number of subjects: 12
Study 8773735 — intervention group
Group type: COMPARATOR
Intervention: No eggs (Control)
Number of subjects: 12
Study 1297887 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 60
Study 1297887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 60
Study 1297887 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 60
Study 1297887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine + Propranolol
Number of subjects: 60
Study 1297887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine + Verapamil
Number of subjects: 60
Study 6338064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfur-salicylic acid shampoo
Number of subjects: 38
Study 6338064 — intervention group
Group type: COMPARATOR
Intervention: Bland oil-in-water lotion (placebo)
Number of subjects: 38
Study 31204331 — intervention group
Group type: EXPERIMENTAL
Intervention: Alchornea laxiflora
Number of subjects: 20
Study 31204331 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanthoxylum zanthoxyloides
Number of subjects: 20
Study 31204331 — intervention group
Group type: EXPERIMENTAL
Intervention: Anogeissus leocarpus
Number of subjects: 20
Study 31204331 — intervention group
Group type: EXPERIMENTAL
Intervention: Masularia acuminate
Number of subjects: 20
Study 31204331 — intervention group
Group type: COMPARATOR
Intervention: Non-herbal fluoridated toothpaste
Number of subjects: 20
Study 30938602 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer-based education material (ICB-EM)
Number of subjects: 96
Study 30938602 — intervention group
Group type: COMPARATOR
Intervention: British Orthodontic Society (BOS) hypodontia leaflet
Number of subjects: 96
Study 27036970 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help program for people with HIV and depressive symptoms, duration 6 to 10 weeks, with weekly motivational support from a coach.
Number of subjects: 0
Study 27036970 — intervention group
Group type: COMPARATOR
Intervention: Waiting list-control group receiving minimal support from a coach for 8 weeks.
Number of subjects: 0
Study 24842985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 807
Study 24842985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 807
Study 24842985 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 807
Study 22314532 — intervention group
Group type: COMPARATOR
Intervention: GSK2248761 30 mg QD for 7 days
Number of subjects: 18
Study 22314532 — intervention group
Group type: COMPARATOR
Intervention: GSK2248761 100 mg QD for 7 days
Number of subjects: 18
Study 22314532 — intervention group
Group type: COMPARATOR
Intervention: GSK2248761 200 mg QD for 7 days
Number of subjects: 18
Study 22314532 — intervention group
Group type: COMPARATOR
Intervention: GSK2248761 400 mg QD for 7 days
Number of subjects: 18
Study 22314532 — intervention group
Group type: COMPARATOR
Intervention: GSK2248761 800 mg QD for 7 days
Number of subjects: 18
Study 22314532 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2248761 (all doses)
Number of subjects: 18
Study 19596459 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted nutritional intervention (chocolate, homemade oral supplements), group exercise (moderate intensity), and oral care
Number of subjects: 121
Study 19596459 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 17671058 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nasal continuous positive airway pressure preceded by a sustained inflation through a nasopharyngeal tube
Number of subjects: 207
Study 17671058 — intervention group
Group type: COMPARATOR
Intervention: Repeated manual inflations with a self‐inflating bag and mask followed by nasal continuous positive airway pressure
Number of subjects: 207
Study 16249086 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examinations
Number of subjects: 24
Study 12075641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml
Number of subjects: 120
Study 12075641 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 5 mg/ml
Number of subjects: 120
Study 11107573 — intervention group
Group type: COMPARATOR
Intervention: Mild ischemic stroke patients
Number of subjects: 40
Study 11107573 — intervention group
Group type: COMPARATOR
Intervention: Severe ischemic stroke patients
Number of subjects: 40
Study 7769797 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 30 mg
Number of subjects: 12
Study 7769797 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 100 mg
Number of subjects: 12
Study 7769797 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 300 mg
Number of subjects: 12
Study 7769797 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 600 mg
Number of subjects: 12
Study 7769797 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 1,000 mg
Number of subjects: 12
Study 7769797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2155645 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity chemotherapy (cisplatin 120 mg m‐2 i.v. day 1, cyclophosphamide 1,000 mg‐2 i.v. day 1, given at 21‐day intervals for six cycles)
Number of subjects: 19
Study 2155645 — intervention group
Group type: COMPARATOR
Intervention: High intensity chemotherapy
Number of subjects: 19
Study 6107853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (1 g three times a day for six weeks)
Number of subjects: 32
Study 6107853 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (0.5 g suppositories three times a day for six weeks)
Number of subjects: 32
Study 6107853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfapyridine (0.5 g three times a day for six weeks)
Number of subjects: 32
Study 6107853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 32
Study 6107853 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid
Number of subjects: 32
Study 6107853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfapyridine
Number of subjects: 32
Study 30431398 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised carbohydrate-rich breakfast (BT; 831±67 kcal eaten before 09:00)
Number of subjects: 10
Study 30431398 — intervention group
Group type: COMPARATOR
Intervention: No-breakfast (NBT; extended overnight fast until 12:00)
Number of subjects: 10
Study 27859929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic‐induced isosmotic dehydration to lower SkBF (DEH)
Number of subjects: 7
Study 27859929 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 7
Study 27859929 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous saline infusion to maintain SkBF (SAL)
Number of subjects: 7
Study 26471400 — intervention group
Group type: EXPERIMENTAL
Intervention: left dorsolateral prefrontal (DLPF) tDCS
Number of subjects: 21
Study 23376338 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPP intervention (one-day cognitive behavioral program and three follow-up group sessions)
Number of subjects: 31
Study 23376338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 31
Study 20648661 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 113
Study 20648661 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose of vitamin D (880 IU/day)
Number of subjects: 113
Study 20648661 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of vitamin D (1600 IU/day)
Number of subjects: 113
Study 20648661 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 113
Study 18931099 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg b.i.d.)
Number of subjects: 14
Study 18931099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17377114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% preservative-free 2-chloroprocaine
Number of subjects: 30
Study 17377114 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine
Number of subjects: 30
Study 15472161 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 302
Study 11452709 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 12‐9566 (50 mg single oral dose)
Number of subjects: 36
Study 11452709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11452709 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 12‐9566
Number of subjects: 36
Study 9931887 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal pouch interposition between esophagus and duodenum
Number of subjects: 0
Study 9931887 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 0
Study 8072252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombolysis (M) using heparinized saline as the pulsing agent
Number of subjects: 103
Study 8072252 — intervention group
Group type: COMPARATOR
Intervention: Pharmacomechanical thrombolysis (PM) using concentrated urokinase as the pulsing agent
Number of subjects: 103
Study 8072252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombolysis (M)
Number of subjects: 103
Study 8072252 — intervention group
Group type: COMPARATOR
Intervention: Pharmacomechanical thrombolysis (PM)
Number of subjects: 103
Study 2522475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide, 60 micrograms by metered-dose inhaler
Number of subjects: 9
Study 2522475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2522475 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfur dioxide (SO2) exposure at 0, 0.5, and 1.0 ppm
Number of subjects: 9
Study 30253985 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable Video Media (PVM)
Number of subjects: 54
Study 30253985 — intervention group
Group type: COMPARATOR
Intervention: Standard Verbal Communication (SVC)
Number of subjects: 54
Study 27730665 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-389949
Number of subjects: 0
Study 26700838 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22963235 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher patient self-efficacy for eating healthy
Number of subjects: 255
Study 22963235 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse greater perceived support for eating healthy
Number of subjects: 255
Study 22963235 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patient age
Number of subjects: 255
Study 22963235 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal blood pressure
Number of subjects: 255
Study 21481716 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol test drink (50 g)
Number of subjects: 30
Study 21481716 — intervention group
Group type: COMPARATOR
Intervention: Glucose test drink (50 g)
Number of subjects: 30
Study 19656102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of stem cells
Number of subjects: 0
Study 19656102 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 0
Study 16917170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin instillation therapy
Number of subjects: 6
Study 16917170 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal vestibular evoked myogenic potentials before therapy
Number of subjects: 6
Study 16917170 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 6
Study 14972474 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative antibiotics (cefazolin and ciprofloxacin)
Number of subjects: 517
Study 14972474 — intervention group
Group type: COMPARATOR
Intervention: No perioperative antibiotics (control group)
Number of subjects: 517
Study 11284596 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-based composite
Number of subjects: 83
Study 11284596 — intervention group
Group type: COMPARATOR
Intervention: Standard hemostatic methods (electrocautery and collagen sponge)
Number of subjects: 83
Study 9134237 — intervention group
Group type: EXPERIMENTAL
Intervention: Test participants
Number of subjects: 528
Study 9134237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 528
Study 8424024 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal feed between 10 PM and 12 AM, gradual lengthening of nighttime feed intervals, alternative caretaking behaviors, maximizing environmental differences between day and night
Number of subjects: 26
Study 8424024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 26
Study 8424024 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 26
Study 2820298 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenge (23 mg of elemental zinc), administered 8 times per day for 5 days (trial 1)
Number of subjects: 0
Study 2820298 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenge (23 mg of elemental zinc), administered 8 times per day for 7 days (trial 2)
Number of subjects: 0
Study 2820298 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenge (23 mg of elemental zinc)
Number of subjects: 0